نتایج جستجو برای: ifnl3
تعداد نتایج: 233 فیلتر نتایج به سال:
Treatment of chronic hepatitis C virus (HCV) infection is evolving rapidly with the development of novel direct acting antivirals (DAAs), however viral clearance remains intimately linked to the hepatic innate immune system. Patients demonstrating a high baseline activation of interferon stimulated genes (ISGs), termed interferon refractoriness, are less likely to mount a strong antiviral respo...
Globally, over 4% of the world population is affected by hepatitis C virus (HCV) infection. The current standard of care for hepatitis C infection is combination therapy with pegylated interferon and ribavirin for 48 weeks, which yield a sustained virological response in only a little over half of the patients with genotype 1 HCV. We investigated the clinical importance of pharmacogenetics in t...
conclusions this study demonstrated the detection of hcv-specific ifn-γ responses in hcv antibody and rna negative individuals, with a tendency for hcv-specific ifn-γ responses to be associated with hcv exposure. the potential role of hcv-specific ifn-γ responses in those who remained hcv rna negative is of value for the development of novel hcv therapeutics. objectives in a cohort of hcv antib...
Abstract Background and Aims A recent study from a large cohort published by the Ubiquitous Pharmacogenomic Consortium demonstrates interest of pre-emptive pharmacogenetic panel testing, with 30% reduction rate clinically detectable side-effects. Our laboratory routinely performs diagnostic exome sequencing (ES) for adult patient kidney disease more than 2000 patients have been analyzed to date...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید